￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What are the common side effects of Erdafitinib/Bocco?

2026-02-01 22:25:32

Check Details
Dacomitinib/Dacomitinib (Dozerun) side effects and treatment methods

2026-02-01 22:25:32

Check Details
Conditions for medical insurance reimbursement of Entrectinib

2026-02-01 22:25:32

Check Details
Is brigatinib/brigatinib an imported drug or a domestic drug?

2026-02-01 22:25:32

Check Details
Comparison of camrelizumab combined with rivoceranib and sorafenib in first-line treatment of unresectable hepatocellular carcinoma

2026-02-01 22:25:32

Check Details
Introduction to the standard usage and dosage of Pemetinib/Dabotan

2026-02-01 22:25:32

Check Details
Analysis of the relationship between Erdafitinib and BOC

2026-02-01 22:25:32

Check Details
Dacomitinib/Dacomitinib (Dozerun) drug efficacy and main treatment directions

2026-02-01 22:25:32

Check Details
Is entrectinib/Luoshengquan a targeted drug or a chemotherapy drug?

2026-02-01 22:25:32

Check Details
How brigatinib/brigatinib (Embry) accurately acts and kills cancer cells

2026-02-01 22:25:32

Check Details
Research on Breast Cancer Indications of Everolimus/Afinitor

2026-02-01 22:25:32

Check Details
Precautions for four groups of people who should not take Anagrelide

2026-02-01 22:25:32

Check Details
Category
相关知识